U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Triple-Negative Breast Carcinoma

MedGen UID:
1711485
•Concept ID:
C5238244
•
Neoplastic Process
Synonym: Refractory Triple Negative Breast Carcinoma

Definition

Triple-negative breast carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Triple-Negative Breast Carcinoma

Professional guidelines

PubMed

Triple negative breast cancer: approved treatment options and their mechanisms of action.
Mandapati A, Lukong KE
J Cancer Res Clin Oncol 2023 Jul;149(7):3701-3719. Epub 2022 Aug 17 doi: 10.1007/s00432-022-04189-6. PMID: 35976445Free PMC Article
EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.
Zhang C, Sheng W, Al-Rawe M, Mohiuddin TM, Niebert M, Zeppernick F, Meihold-Heerlein I, Hussain AF
Int J Mol Sci 2022 May 30;23(11) doi: 10.3390/ijms23116122. PMID: 35682800Free PMC Article
Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
De Luca A, D'Alessio A, Maiello MR, Gallo M, Chicchinelli N, Pergameno M, Piccirilli MS, Normanno N
Expert Opin Drug Metab Toxicol 2015 Jul;11(7):1177-85. doi: 10.1517/17425255.2015.1057497. PMID: 26073581

Recent clinical studies

Etiology

An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer.
Cheng SX, Chen QC, Lin GH, Han YH, Wang BC, Dai Y, Zhao YX
Medicine (Baltimore) 2023 Jul 28;102(30):e34486. doi: 10.1097/MD.0000000000034486. PMID: 37505137Free PMC Article
EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.
Zhang C, Sheng W, Al-Rawe M, Mohiuddin TM, Niebert M, Zeppernick F, Meihold-Heerlein I, Hussain AF
Int J Mol Sci 2022 May 30;23(11) doi: 10.3390/ijms23116122. PMID: 35682800Free PMC Article
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators
N Engl J Med 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM
Cell Res 2021 Feb;31(2):178-186. Epub 2020 Jul 27 doi: 10.1038/s41422-020-0375-9. PMID: 32719455Free PMC Article
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K
N Engl J Med 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213. PMID: 30786188

Diagnosis

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J
Breast Cancer Res Treat 2022 Sep;195(2):127-139. Epub 2022 May 11 doi: 10.1007/s10549-022-06602-7. PMID: 35545724Free PMC Article
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM
Cell Res 2021 Feb;31(2):178-186. Epub 2020 Jul 27 doi: 10.1038/s41422-020-0375-9. PMID: 32719455Free PMC Article
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, Song J, Yang JM
Drug Resist Updat 2017 May;32:1-15. Epub 2017 Aug 19 doi: 10.1016/j.drup.2017.07.002. PMID: 29145974
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT
J Clin Oncol 2017 Jul 1;35(19):2141-2148. Epub 2017 Mar 14 doi: 10.1200/JCO.2016.70.8297. PMID: 28291390Free PMC Article
FGF receptors: cancer biology and therapeutics.
Katoh M, Nakagama H
Med Res Rev 2014 Mar;34(2):280-300. Epub 2013 May 21 doi: 10.1002/med.21288. PMID: 23696246

Therapy

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators
N Engl J Med 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM
Cell Res 2021 Feb;31(2):178-186. Epub 2020 Jul 27 doi: 10.1038/s41422-020-0375-9. PMID: 32719455Free PMC Article
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K
N Engl J Med 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213. PMID: 30786188
Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem 2017;17(2):152-163. doi: 10.2174/1871520616666160502122724. PMID: 27137076
FGF receptors: cancer biology and therapeutics.
Katoh M, Nakagama H
Med Res Rev 2014 Mar;34(2):280-300. Epub 2013 May 21 doi: 10.1002/med.21288. PMID: 23696246

Prognosis

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ, Shao ZM
Cell Metab 2023 Jan 3;35(1):84-100.e8. Epub 2022 Oct 17 doi: 10.1016/j.cmet.2022.09.021. PMID: 36257316
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators
N Engl J Med 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM
Cell Res 2021 Feb;31(2):178-186. Epub 2020 Jul 27 doi: 10.1038/s41422-020-0375-9. PMID: 32719455Free PMC Article
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K
N Engl J Med 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213. PMID: 30786188
Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem 2017;17(2):152-163. doi: 10.2174/1871520616666160502122724. PMID: 27137076

Clinical prediction guides

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, O'Shaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart MJ
Eur J Cancer 2023 Jan;178:23-33. Epub 2022 Oct 18 doi: 10.1016/j.ejca.2022.10.003. PMID: 36379186
Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ, Shao ZM
Cell Metab 2023 Jan 3;35(1):84-100.e8. Epub 2022 Oct 17 doi: 10.1016/j.cmet.2022.09.021. PMID: 36257316
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J
Breast Cancer Res Treat 2022 Sep;195(2):127-139. Epub 2022 May 11 doi: 10.1007/s10549-022-06602-7. PMID: 35545724Free PMC Article
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM
Cell Res 2021 Feb;31(2):178-186. Epub 2020 Jul 27 doi: 10.1038/s41422-020-0375-9. PMID: 32719455Free PMC Article
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT
J Clin Oncol 2017 Jul 1;35(19):2141-2148. Epub 2017 Mar 14 doi: 10.1200/JCO.2016.70.8297. PMID: 28291390Free PMC Article

Recent systematic reviews

Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis.
Kathpalia M, Sharma A, Kaur N
Ann Pharmacother 2024 Jan;58(1):44-53. Epub 2023 Apr 6 doi: 10.1177/10600280231164110. PMID: 37026168

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...